Nevada Board of Pharmacy notice of hearing: proposed NAC 453.510 Schedule I additions (dipentylone + seven fentanyl-related substances)

The Nevada State Board of Pharmacy issued a Notice of Intent to Act Upon a Regulation / Notice of Hearing (LCB File No. R107-25) proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, stated to be in conformity with federal regulations. A public hearing is scheduled for March 5, 2026, and written comments are due on or before March 5, 2026. Compliance teams should monitor this rulemaking because, if adopted, the substances would become explicitly controlled under Nevada Schedule I, affecting handling prohibitions/controls, registration, security, and recordkeeping obligations under NRS/NAC 453 for registrants and other regulated entities.